Servier Revenue and Competitors
Estimated Revenue & Valuation
- Servier's estimated annual revenue is currently $3.1B per year.
- Servier's estimated revenue per employee is $201,000
Employee Data
- Servier has 15221 Employees.
- Servier grew their employee count by 2% last year.
Servier's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Executive Assistant to CEO, HR Director & Legal & Compliance Manager | Reveal Email/Phone |
2 | CFO Servier Mexico | Reveal Email/Phone |
3 | Chief Staff to CMC | Reveal Email/Phone |
4 | Head Innovation Life Cycle Management, VP R&D | Reveal Email/Phone |
5 | Chief Scientist Rare Diseases | Reveal Email/Phone |
6 | Chief Staff Generic’s Division | Reveal Email/Phone |
7 | Chief Staff, Research | Reveal Email/Phone |
8 | Chief Patient Officer | Reveal Email/Phone |
9 | Servier Industry Chief Staff | Reveal Email/Phone |
10 | Chief Staff R&D Oncology | Reveal Email/Phone |
Servier Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $413.3M | 324 | 0% | $634M | N/A |
#2 | $47.8M | 238 | 0% | N/A | N/A |
#3 | $2.4M | 12 | -52% | N/A | N/A |
#4 | $25.7M | 128 | 39% | N/A | N/A |
#5 | $12.9M | 64 | 129% | N/A | N/A |
#6 | $23.9M | 119 | 8% | $113M | N/A |
#7 | $0.3M | 3 | 0% | N/A | N/A |
#8 | $10.3M | 51 | -14% | N/A | N/A |
#9 | $1.8M | 367 | -4% | $538M | N/A |
#10 | $50M | 249 | 3% | N/A | N/A |
What Is Servier?
We are an international pharmaceutical company governed by a non-profit Foundation and headquartered in France. With a strong international presence in 148 countries and a turnover of 4 billion euros in 2016, we employ over 21,000 people worldwide. Being completely independent, we invest 25% of turnover (excluding generics) in Research and Development and use all our profits in growth. We are specialised and driven by our constant search for innovation in five major research areas: cardiovascular diseases, cancers, diabetes, immuno-inflammatory diseases and neurodegenerative diseases, as well as by our activities in high quality generic drugs. Currently, we have 23 drug candidates including 19 new molecular entities at various stages of clinical development. Our priorities are pathologies with high medical needs within our areas of expertise. Medication for cardiological and rheumatological conditions, as well as for diabetes and clinical depression
keywords:N/A
N/A
Total Funding
15221
Number of Employees
$3.1B
Revenue (est)
2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Servier News
Servier is poised to go to market with a new indication after the Phase III trial of a trial of its leukemia drug in IDH1-mutated acute...
Mécénat Servier Charity Fund was created in 2016 to centralize and coordinate the Group's philanthropic initiatives. Five years later, Servier is...
Servier condemns this war and calls for a prompt return to peace. All our thoughts go out to those affected by this brutal and tragic situation,...
Servier, a Paris, France-based independent international pharmaceutical company, completed the acquisition of Symphogen A/S. The amount of the deal was not disclosed. Symphogen will now function as Servier’s antibody center of excellence across multiple therapeutic areas, including oncology. S ...
PARIS & BOSTON–(BUSINESS WIRE)–January 9, 2019– WeHealth by Servier, the e-health department of Servier Group, and PathMaker Neurosystems, a pioneering clinical-stage bioelectronic medicine company, announced today the closing of a partnership agreement to develop and commercialize the first ne ...
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $14130M | 15357 | -6% | $1.7B |
#2 | $4919.3M | 19521 | 89% | N/A |
#3 | $7595.5M | 20094 | N/A | N/A |
#4 | $7679.1M | 20315 | 5% | N/A |
#5 | $4390M | 22226 | 7% | $3.2B |